Exelixis Inc Increase (Decrease) in Accrued Liabilities
Exelixis Inc (EXEL) reported Increase (Decrease) in Accrued Liabilities of -$5.26 million for the 6-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-05
- Exelixis Inc increase (decrease) in accrued liabilities for the quarter ending 2026-07-03 was -$9.31M.
- Exelixis Inc increase (decrease) in accrued liabilities for the quarter ending 2026-04-03 was $4.04M, a 12.18% decline year-over-year.
- Exelixis Inc increase (decrease) in accrued liabilities for the quarter ending 2026-01-02 was $355.00K, a 58.43% decline year-over-year.
- Exelixis Inc increase (decrease) in accrued liabilities for the quarter ending 2025-10-03 was $903.00K, a 32.96% decline year-over-year.
- Exelixis Inc increase (decrease) in accrued liabilities for fiscal 2026 was $1.90M.
- Exelixis Inc increase (decrease) in accrued liabilities for fiscal 2025 was -$149.00K, a 111.08% decline from fiscal 2023.
- Exelixis Inc increase (decrease) in accrued liabilities for fiscal 2023 was $1.34M.
- Exelixis Inc increase (decrease) in accrued liabilities for fiscal 2022 was -$63.06M, a 189.71% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-07-03 | -$9.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$5.26M 10-Q · filed 2026-08-05 | -$4.91M derived: sum of 3 quarters · filed 2026-08-05 | -$4.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-04-03 | $4.04M 10-Q · filed 2026-05-05 | $4.40M derived: sum of 2 quarters · filed 2026-05-05 | $5.30M derived: sum of 3 quarters · filed 2026-05-05 | $1.34M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-01-02 | $355.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $1.26M derived: sum of 2 quarters · filed 2026-02-10 | -$2.71M derived: sum of 3 quarters · filed 2026-08-05 | $1.90M 10-K · filed 2026-02-10 |
| 2025-10-03 | $903.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$3.06M derived: sum of 2 quarters · filed 2026-08-05 | $1.54M 10-Q · filed 2025-11-04 | $2.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-07-04 | -$3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $641.00K 10-Q · filed 2026-08-05 | $1.50M derived: sum of 3 quarters · filed 2026-08-05 | $2.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-04-04 | $4.61M 10-Q · filed 2026-05-05 | $5.46M derived: sum of 2 quarters · filed 2026-05-05 | $6.81M derived: sum of 3 quarters · filed 2026-05-05 | $8.29M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-01-03 | $854.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $2.20M derived: sum of 2 quarters · filed 2026-02-10 | $3.68M derived: sum of 3 quarters · filed 2026-02-10 | -$149.00K 10-K · filed 2026-02-10 |
| 2024-09-27 | $1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.83M derived: sum of 2 quarters · filed 2025-11-04 | -$1.00M 10-Q · filed 2025-11-04 | -$739.00K derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-28 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | -$2.35M 10-Q · filed 2025-07-28 | -$2.09M derived: sum of 3 quarters · filed 2026-02-10 | -$4.28M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-29 | -$3.83M 10-Q · filed 2025-05-13 | -$3.56M derived: sum of 2 quarters · filed 2026-02-10 | -$5.76M derived: sum of 3 quarters · filed 2026-02-10 | -$620.00K derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-29 | $264.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | -$1.93M derived: sum of 2 quarters · filed 2026-02-10 | $3.21M derived: sum of 3 quarters · filed 2026-02-10 | $1.34M 10-K · filed 2026-02-10 |
| 2023-09-29 | -$2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $2.94M derived: sum of 2 quarters · filed 2024-10-29 | $1.08M 10-Q · filed 2024-10-29 | |
| 2023-06-30 | $5.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.27M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | -$1.86M 10-Q · filed 2024-04-30 | |||
| 2022-12-30 | -$63.06M 10-K · filed 2025-02-11 | |||
| 2022-04-01 | -$54.26M 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $70.30M 10-K · filed 2024-02-06 | |||
| 2021-04-02 | $1.00M 10-Q · filed 2022-05-10 | |||
| 2021-01-01 | $600.00K 10-K · filed 2023-02-07 | |||
| 2020-01-03 | $4.44M 10-K · filed 2022-02-18 | |||
| 2016-03-31 | -$1.94M 10-Q · filed 2016-05-04 | -$13.65M derived: sum of 2 quarters · filed 2016-05-04 | -$16.44M derived: sum of 3 quarters · filed 2016-05-04 | -$14.84M derived: sum of 4 quarters · filed 2016-05-04 |
| 2015-12-31 | -$11.72M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$14.50M derived: sum of 2 quarters · filed 2016-02-29 | -$12.90M derived: sum of 3 quarters · filed 2016-02-29 | -$23.47M 10-K · filed 2016-02-29 |
| 2015-09-30 | -$2.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$1.19M derived: sum of 2 quarters · filed 2015-11-10 | -$11.76M 10-Q · filed 2015-11-10 | -$15.31M derived: sum of 4 quarters · filed 2016-05-04 |
| 2015-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | -$8.97M 10-Q · filed 2015-08-11 | -$12.53M derived: sum of 3 quarters · filed 2016-05-04 | -$8.79M derived: sum of 4 quarters · filed 2016-05-04 |
| 2015-03-31 | -$10.57M 10-Q · filed 2016-05-04 | -$14.13M derived: sum of 2 quarters · filed 2016-05-04 | -$10.39M derived: sum of 3 quarters · filed 2016-05-04 | -$8.14M derived: sum of 4 quarters · filed 2016-05-04 |
| 2014-12-31 | -$3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $178.00K derived: sum of 2 quarters · filed 2016-02-29 | $2.43M derived: sum of 3 quarters · filed 2016-02-29 | $6.59M 10-K · filed 2016-02-29 |
| 2014-09-30 | $3.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $5.98M derived: sum of 2 quarters · filed 2015-11-10 | $10.14M 10-Q · filed 2015-11-10 | $10.06M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $6.41M 10-Q · filed 2015-08-11 | $6.33M derived: sum of 3 quarters · filed 2016-02-29 | $11.96M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $4.16M 10-Q · filed 2015-04-30 | $4.08M derived: sum of 2 quarters · filed 2016-02-29 | $9.71M derived: sum of 3 quarters · filed 2016-02-29 | $19.26M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | -$84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $5.55M derived: sum of 2 quarters · filed 2016-02-29 | $15.10M derived: sum of 3 quarters · filed 2016-02-29 | $14.40M 10-K · filed 2016-02-29 |
| 2013-09-30 | $5.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $15.19M derived: sum of 2 quarters · filed 2014-11-04 | $14.48M 10-Q · filed 2014-11-04 | $13.68M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $9.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $8.85M 10-Q · filed 2014-07-31 | $8.04M derived: sum of 3 quarters · filed 2015-03-02 | $7.76M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | -$703.00K 10-Q · filed 2014-05-01 | -$1.51M derived: sum of 2 quarters · filed 2015-03-02 | -$1.79M derived: sum of 3 quarters · filed 2015-03-02 | |
| 2012-12-31 | -$803.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$1.09M derived: sum of 2 quarters · filed 2015-03-02 | $1.17M 10-K · filed 2015-03-02 | |
| 2012-09-30 | -$287.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $1.97M 10-Q · filed 2013-10-30 | ||
| 2012-06-30 | $2.26M 10-Q · filed 2013-08-06 | |||
| 2011-12-31 | $9.25M 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |